Faster Approval Process Contributing to Biotech Industry's Success in 2012

The Paragon Report Provides Stock Research on Rosetta Genomics and MannKind

Marketwired

NEW YORK, NY--(Marketwire - Sep 10, 2012) - Despite concerns of a global economic slowdown the Biotech Industry has impressed investors with strong gains in 2012. Patent expirations, favorable legislation, and a faster review process have been some of the contributing factors for the industry's current boom. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on Rosetta Genomics Ltd. (NASDAQ: ROSG) and MannKind Corporation (NASDAQ: MNKD).

Access to the full company reports can be found at:
www.ParagonReport.com/ROSG
www.ParagonReport.com/MNKD

The Food and Drug Administration Safety and Innovation Act (FDASIA) was signed into law on July 9, 2012 by President Obama. The law allows the FDA to collect "user fees" to help fund reviews of innovator drugs, medical devices, generic drugs and biosimilars.

"The legislation will enhance the development and review of innovative new therapies through increased transparency and scientific dialogue, advancements in regulatory science and strengthened post-market review. It will also increase the Food and Drug Administration's (FDA) access to external expertise to improve the drug review process," Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood said in a statement.

Paragon Report releases regular market updates on the Biotechnology Industry so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.ParagonReport.com and get exclusive access to our numerous stock reports and industry newsletters.

Rosetta develops and commercializes a full range of microRNA-based molecular diagnostics. Rosetta's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Aegis Capital's recently initiated coverage on the company with a buy rating and a price target of $16.00.

MannKind Corporation focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes and cancer. The company's lead investigational product candidate AFREZZA is in late stage clinical investigation for the treatment of adults with type 1 or type 2 diabetes.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at:
http://www.paragonreport.com/disclaimer

View Comments